Dorsomorphin (Compound C): Precision AMPK and BMP Inhibition for Mitochondrial Quality Control and Muscle Metabolism

Introduction

As metabolic and degenerative diseases surge globally, dissecting the molecular underpinnings of autophagy, energy homeostasis, and stem cell fate has become central to translational research. Dorsomorphin (Compound C), a potent ATP-competitive AMPK inhibitor and BMP signaling pathway modulator, has emerged as an indispensable chemical probe for interrogating these complex biological processes. While previous reviews have highlighted Dorsomorphin’s dual-pathway inhibition in metabolic syndromes and stem cell biology, this article takes a distinct, systems-level perspective: we focus on the intersection of AMPK signaling, mitophagy, and mitochondrial quality control in muscle and metabolic health, integrating the latest mechanistic insights from recent research. We further provide an analytical comparison to alternative tools and discuss best practices for experimental deployment in advanced disease models.

Mechanism of Action of Dorsomorphin (Compound C)

AMPK Inhibition: ATP-Competitive and Highly Selective

Dorsomorphin (Compound C), cataloged as B3252, acts as a reversible, cell-permeable, ATP-competitive inhibitor of AMP-activated protein kinase (AMPK), with a Ki of 109 nM. Its selectivity for AMPK is well-established, displaying minimal off-target activity against structurally related kinases such as protein kinase A, protein kinase C, and Janus kinase 3. By binding the ATP site of AMPK, Dorsomorphin effectively blocks kinase activation and downstream phosphorylation events, notably inhibiting acetyl-CoA carboxylase (ACC) phosphorylation by up to 80%. This action impedes key metabolic processes, including fatty acid synthesis and autophagic proteolysis, and thereby modulates cellular energy balance and stress responses.

BMP/Smad Signaling Inhibition

In parallel, Dorsomorphin disrupts bone morphogenetic protein (BMP) signaling by preventing phosphorylation of Smad 1/5/8, critical effectors in the BMP/Smad signaling pathway. This dual inhibition suppresses heterotopic ossification and downregulates hepatic hepcidin gene transcription, leading to increased serum iron levels. These effects have profound implications for iron metabolism modulation and the regulation of stem cell fate, including the promotion of self-renewal and neural differentiation in human embryonic stem cells.

Solubility and Handling

Dorsomorphin is insoluble in water and ethanol but dissolves readily in DMSO (≥8.49 mg/mL) with gentle warming and ultrasonic agitation. It is supplied as a solid and should be stored at -20°C; solutions are best used promptly to avoid degradation.

Integration of Dorsomorphin in Mitochondrial Quality Control and Muscle Metabolism Research

The AMPK/PINK1/Parkin-Mitophagy Axis

Mitochondrial homeostasis is governed by selective autophagy (mitophagy), which eliminates damaged or dysfunctional mitochondria, preserving cellular energy balance. The AMPK/PINK1/Parkin pathway is a principal regulator of mitophagy. AMPK activation promotes PINK1 stabilization and Parkin recruitment to depolarized mitochondria, driving their autophagic clearance.

A recent pivotal study (Ren et al., 2025) elucidated the centrality of this pathway in skeletal muscle metabolism: Lycium barbarum polysaccharide mitigated high-fat-diet-induced muscle atrophy by promoting AMPK/PINK1/Parkin-mediated mitophagy. Notably, the protective effects of this intervention were abolished by pharmacological AMPK inhibition using Dorsomorphin (Compound C), confirming the compound’s utility as a mechanistic tool to dissect AMPK-dependent mitophagy and mitochondrial quality control in vivo and in vitro.

Experimental Applications: Precision Interrogation of AMPK and Autophagy

• Inhibition of AMPK in Hepatocytes and Muscle Cells: Dorsomorphin is routinely deployed at 4–40 μM in cell culture and 10 mg/kg intraperitoneally in animal models. Its use enables precise inhibition of AMPK activity in hepatocytes, muscle, and cancer cell lines, facilitating the study of energy metabolism and autophagy regulation.
• Dissecting BMP4-Induced SMAD Phosphorylation: With an IC₅₀ of 0.47 μM for BMP4-induced SMAD phosphorylation inhibition, Dorsomorphin is an ideal probe for evaluating BMP/Smad signaling in stem cell self-renewal, neural induction, and ossification models.
• Autophagy and Mitophagy Modulation: By blocking AMPK, Dorsomorphin halts AMPK-driven phosphorylation cascades (e.g., ACC phosphorylation inhibition), providing a means to dissect the role of AMPK in initiating mitophagic flux, as demonstrated in metabolic disease and sarcopenic obesity models.
• Iron Metabolism Studies: Dorsomorphin’s ability to suppress hepatic hepcidin transcription and elevate serum iron expands its utility into studies of systemic iron homeostasis.

Comparative Analysis: Dorsomorphin Versus Alternative AMPK/BMP Inhibitors

While several alternative AMPK inhibitors exist (e.g., Compound B, SBI-0206965), Dorsomorphin (Compound C) remains the gold standard for dual-pathway inhibition of both AMPK and BMP/Smad signaling. Its ATP-competitive mechanism and high selectivity minimize confounding off-target effects—a limitation of older, less selective compounds. Unlike genetic knockdown or CRISPR-Cas9 approaches, which require significant time and resources, Dorsomorphin allows for rapid, reversible, and tunable inhibition, offering temporal control in both acute and chronic studies.

Moreover, while other BMP inhibitors exist (e.g., LDN-193189), few combine this functionality with potent AMPK inhibition, making Dorsomorphin uniquely suited for studying intersecting metabolic and developmental pathways. This duality is particularly advantageous in models where metabolic state and cellular differentiation are intertwined, such as in muscle atrophy, cancer research, and neural stem cell differentiation.

Advanced Applications: Dorsomorphin in Translational Muscle and Metabolic Research

Dissecting the Role of AMPK in Skeletal Muscle Atrophy and Sarcopenic Obesity

Recent research has underscored the crucial function of AMPK in maintaining skeletal muscle integrity, especially under metabolic stress. The referenced study (Ren et al., 2025) demonstrated that AMPK-mediated mitophagy is vital for counteracting muscle atrophy induced by high-fat diets. By employing Dorsomorphin as an AMPK inhibitor, researchers confirmed the necessity of this pathway for the protective effects of therapeutic agents (e.g., Lycium barbarum polysaccharide) on mitochondrial structure and function. This positions Dorsomorphin as an essential tool for probing the mechanistic links between energy metabolism, autophagy regulation, and muscle health.

Cancer Research: AMPK and BMP Pathways as Therapeutic Targets

In cancer biology, the AMPK signaling pathway regulates tumor cell metabolism, proliferation, and survival under nutrient stress. Dorsomorphin’s ability to inhibit both AMPK and BMP/Smad signaling allows researchers to discern how metabolic and developmental cues converge in cancer progression. This dual inhibition is especially relevant in studies where metabolic reprogramming and epithelial-mesenchymal transition (EMT) are key investigative foci.

Neural Stem Cell Differentiation and Regeneration

Dorsomorphin’s BMP signaling inhibition has been leveraged to promote self-renewal and neural induction in human embryonic stem cells. By suppressing BMP4-SMAD signaling, Dorsomorphin facilitates the maintenance of pluripotency and the directed differentiation of neural lineages, advancing protocols for regenerative medicine and neural tissue engineering.

Iron Metabolism Modulation

The suppression of hepatic hepcidin transcription by Dorsomorphin, leading to increased serum iron, extends its applications into the study of systemic iron regulation and anemia. Its dual action enables experimental models that interrogate the interplay between metabolic state, iron homeostasis, and erythropoiesis.

Strategic Guidance for Experimental Design

• Concentration Optimization: Begin with a titration (4–40 μM) in cell models to balance pathway inhibition with cytotoxicity. For in vivo studies, 10 mg/kg intraperitoneally is standard, but pilot dosing is recommended.
• Temporal Control: Leverage Dorsomorphin’s reversible inhibition to dissect acute versus chronic pathway dependencies.
• Pathway Cross-Talk: Use in combination with genetic tools or alternative inhibitors to parse AMPK-dependent versus BMP-dependent effects.
• Downstream Readouts: Monitor ACC phosphorylation, autophagic flux (e.g., LC3-II/I ratio), SMAD1/5/8 phosphorylation, and iron-related gene expression.

Contextualizing Within the Content Landscape

While previous works—such as "Dorsomorphin (Compound C): Strategic Deployment of Dual-Pathway Inhibition"—have mapped the compound’s dual mechanistic features and provided strategic recommendations for translational research, our article pushes the frontier further by anchoring the discussion in mitochondrial quality control and the AMPK/PINK1/Parkin axis, a critical yet underexplored dimension.

Similarly, the analysis presented in "Advanced Insights into AMPK and BMP Pathways" delivers a comprehensive overview of Dorsomorphin’s roles in metabolic regulation and stem cell biology. However, our focus on experimental strategies to interrogate mitophagy, muscle atrophy, and mitochondrial dynamics offers a unique, actionable perspective for researchers aiming to unravel the molecular basis of sarcopenic obesity and related disorders.

For a foundational technical guide to troubleshooting and maximizing the experimental impact of Dorsomorphin, readers may also consult "Dorsomorphin (Compound C): Powerful AMPK Inhibitor for Metabolic and Stem Cell Research". Our article builds upon this by integrating the most recent peer-reviewed evidence and offering a systems-level synthesis of Dorsomorphin’s applications in mitochondrial quality control.

Conclusion and Future Outlook

Dorsomorphin (Compound C) stands as a uniquely powerful chemical probe for interrogating the AMPK signaling pathway, BMP/Smad axis, and their intersections in metabolic, stem cell, and disease biology. Its dual inhibition profile, high selectivity, and experimental flexibility allow researchers to dissect complex processes such as autophagy regulation, neural stem cell differentiation, and iron metabolism modulation with unprecedented precision. By integrating recent mechanistic insights—particularly the AMPK/PINK1/Parkin mitophagy axis—this article provides a roadmap for leveraging Dorsomorphin in advanced translational and mechanistic studies.

Future directions include combining Dorsomorphin with next-generation genetic and pharmacological tools to further elucidate the nuances of mitochondrial quality control and metabolic resilience. As our understanding of metabolic signaling deepens, Dorsomorphin will continue to anchor innovative experimental strategies at the frontier of muscle biology, cancer research, and regenerative medicine.